{
  "docId": "019de076-2351-76a2-9dc5-1c75bf1dd158",
  "docSlug": "905d9ceaf5cb608feb86b583a8401e54",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 45,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "kpi_overview",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a two-column layout to contrast the overarching strategy with specific investment priorities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2351-76a2-9dc5-1c75bf1dd158/12",
  "deckHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158",
  "deckJsonHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158.json",
  "deckAnchorHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.825
      },
      "kind": "callout",
      "text": "Priority remains reinvesting in our business",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bf13325-e03c-420c-a282-895e2f7f1575",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.51,
        "y": 0.825
      },
      "kind": "callout",
      "text": ">20 new approvals in major markets YTD",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ace05821-3d92-4577-a1d5-23eb2f07dc9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "framework",
      "text": "Capital allocation strategy unchanged",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33e424da-8708-4b00-b18a-503cb350ef6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.44,
        "x": 0.52,
        "y": 0.38
      },
      "kind": "list",
      "text": "Currently >120 projects in Phase II/III development; Investments behind launches; Continued investments in new technologies; Value accretive deals; Leverage partnerships",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45f76fbb-791f-4163-bb4d-0c4371723788",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.04,
        "y": 0.975
      },
      "kind": "source-note",
      "text": "CAPEX = capital expenditure; YTD = year-to-date.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f571aa56-42ec-4994-868b-a34f8e0efb5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.32,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Capital allocation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4e2dac7-b4a7-414b-b4a0-6d68feb414a3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "capital-allocation-framework",
      "slug": null,
      "matchId": "d9ec46da-35ef-4706-8009-7465950b9070",
      "evidence": "The slide explicitly outlines the company's capital allocation strategy and priorities.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4272c71f-edd6-48f7-a353-789a42575177",
      "evidence": "The document walks through a logical chain of financial performance, portfolio evolution, and R&D highlights",
      "position": 0,
      "objective": "How AstraZeneca's diversified portfolio drives growth",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}